Medicus Pharma Ltd (MDCX) Finansal

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.